Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.33 |
| ▸ | PPARG | P37231 | 3/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | ITGAV | P06756 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | RARB | P10826 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221521 | 1.00 | P2RY14 (0.34) | P2RY14S1PR3ITGB3ITGA2BPPARG | |
| SCHEMBL223138 | 0.95 | P2RY14 (0.32) | P2RY14S1PR3ITGB3ITGA2B | |
| SCHEMBL2741111 | 0.95 | P2RY14 (0.32) | P2RY14S1PR3ITGB3ITGA2B | |
| SCHEMBL2763414 | 0.94 | P2RY14 (0.31) | P2RY14S1PR3ITGB3ITGA2B | |
| SCHEMBL222572 | 0.91 | ALDH1A1 (0.32) | RAB9A | |
| SCHEMBL223022 | 0.89 | CYP2C9 (0.33) | S1PR3PPARGPPARA | |
| SCHEMBL223021 | 0.89 | CYP2C9 (0.33) | S1PR3PPARGPPARA | |
| SCHEMBL10138738 | 0.87 | P2RY14 (0.30) | P2RY14 | |
| SCHEMBL2763542 | 0.86 | — | — | |
| SCHEMBL223772 | 0.86 | NPC1 (0.31) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431039-B2 | Mesogenic stabilizers | TRANSITIONS OPTICAL, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431039-B2 | Mesogenic stabilizers | TRANSITIONS OPTICAL, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120002141-A1 | MESOGENIC STABILIZERS | TRANSITIONS OPTICAL, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120002141-A1 | MESOGENIC STABILIZERS | TRANSITIONS OPTICAL, INC. (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120002141-A1 | MESOGENIC STABILIZERS | BMI1, METTL14, PYM1 | P2RY14 2316/4885S1PR3 2409/4885ITGB3 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.